Global Moyamoya Disease Market, By Diagnosis (Cerebral Angiogram, MRI, MRA, CT Scan, Transcranial Doppler Ultrasound, PET Scan, Electroencephalography), Treatment (Surgical, Non-Surgical Treatment), Distribution Channel (Hospitals, Clinics, Diagnostic Centers, Drug Stores, Pharmacies, Others), Country (U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa) Industry Trends and Forecast to 2028
Market Analysis and Insights: Global Moyamoya Disease Market
The moyamoya disease market is expected to gain market growth at a potential rate of 7.10% in the forecast period of 2021 to 2028. Rise in the public awareness and technological advancements is the vital factor escalating the moyamoya disease market growth.
Moyamoya disease (MMD) is defined as a chronic, cerebrovascular disease that is characterized by progressive stenosis in the internal carotid artery and an abnormal vascular network at the base of the brain. The stroke is one of the significant symptoms of moyamoya disease, that further leads to paralysis of the arms, face and legs, loss of speech, and temporary loss of neurologic function of body parts, visual disturbances, headaches, developmental delay, and seizures.
Rise in the research & development and improvement in reimbursement policies in the healthcare will uplift the market growth, also rise in the healthcare outcomes, rise in the support from government and increase in the healthcare outcomes are some of the crucial factors among others driving the moyamoya disease market growth. Moreover, rise in the technological advancements and modernization in the healthcare devices used and rise in the demand from emerging economies will further create new opportunities for the moyamoya disease market in the forecast period of 2021-2028.
However, rise in the side-effects of treatment, increase in the presence of misbranded and spurious drugs, and poor healthcare system in low and middle-income countries, are the major factors among others acting as restraints, and will further challenge the moyamoya disease market in the forecast period mentioned above.
This Moyamoya disease market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis on the moyamoya disease market scenario contact Data bridge market research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Moyamoya Disease Market Scope and Market Size
The moyamoya disease market treatment market is segmented on the basis of diagnosis, treatment and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of diagnosis, the moyamoya disease market is segmented into cerebral angiogram, MRI, MRA, CT scan, transcranial Doppler ultrasound, PET scan and electroencephalography.
- Based on treatment, the moyamoya disease market is segmented into surgical and non-surgical treatment.
The moyamoya disease market is also segmented on the basis of distribution channel into hospitals, clinics, diagnostic centers, drug stores, pharmacies and others.
Moyamoya Disease Market Country Level Analysis
The moyamoya disease market is analysed and market size information is provided by country, diagnosis, treatment and distribution channel as referenced above.
The countries covered in the moyamoya disease market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).
North America dominates the moyamoya disease market due to rise in the awareness among people, and high healthcare expenditure in this region. Asia-Pacific is the expected region in terms of growth in osteoarthritic pain management treatment due to huge patient pool and developing healthcare technology in this region.
The country section of the moyamoya disease market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
The moyamoya disease market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Moyamoya Disease Market Share Analysis
The moyamoya disease market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to moyamoya disease market.
The major players covered in the moyamoya disease market report are Abbott, Pfizer Inc., AstraZeneca, Eli Lilly and Company, Abiogen Pharma S.p.A., Merck Sharp & Dohme Corp., Novartis AG, GlaxoSmithKline plc., Zimmer Biomet, Johnson & Johnson Private Limited, Ampio Pharmaceuticals Inc., Regeneron Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Abbott, AbbVie Inc., Astellas Pharma Inc., BioDelivery Sciences International, Inc.., Crystal Genomics, Daiichi-Sankyo Company Limited, and Endo Pharmaceuticals Inc among other domestic and global players. Osteoarthritic pain management treatment share data is available for global, North America, South America, Europe, Asia-Pacific (APAC) and Middle East and Africa (MEA) separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
SKU-